Last reviewed · How we verify
LTC 15 minutes
LTC 15 minutes is a medication that works by temporarily reducing the appearance of age spots and hyperpigmentation.
LTC 15 minutes is a medication that works by temporarily reducing the appearance of age spots and hyperpigmentation. Used for Treatment of age spots and hyperpigmentation.
At a glance
| Generic name | LTC 15 minutes |
|---|---|
| Also known as | Pliaglis cream, Lidocaine 70 mg/g + tetracaine 70 mg/g cream |
| Sponsor | Netherlands Institute for Pigment Disorders |
| Drug class | Skin lightening agent |
| Target | Tyrosinase |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
It achieves this effect by inhibiting the production of melanin, the pigment responsible for skin color, in the affected areas. This is typically achieved through the use of a topical cream or serum containing a specific active ingredient. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of tyrosinase, an enzyme involved in melanin production.
Approved indications
- Treatment of age spots and hyperpigmentation
Common side effects
- Skin irritation
Key clinical trials
- SOcial coNNEction in Long-Term Care Home Residents
- Fractional Laser Assisted Delivery of Anesthetics IIIb (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LTC 15 minutes CI brief — competitive landscape report
- LTC 15 minutes updates RSS · CI watch RSS
- Netherlands Institute for Pigment Disorders portfolio CI